MTCR Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 Jun 2023 @ 21:11):

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases...

Stats
Tagesvolumen	83 889.00
Durchschnittsvolumen	52 473.00
Marktkapitalisierung	25.48M
EPS	$0 ( 2023-11-13 )
Last Dividend	$0.580 ( 2023-06-21 )
Next Dividend	$0 ( N/A )
P/E	-0.564
ATR14	$0.0160 (2.75%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-23	Klassen Preston	Sell	842 211	Common Stock
2023-03-23	Klassen Preston	Sell	842 211	Stock Option (right to buy)
2023-01-26	York Michael	Sell	107 054	Common Stock
2023-01-26	Klassen Preston	Sell	380 605	Common Stock
2022-12-21	Leonard Braden Michael	Buy	120 099	Common Stock

INSIDER POWER
-16.10
Last 97 transactions
Buy: 12 877 287 \| Sell: 12 262 808

Volumen Korrelation

Lang: -0.64 (weak negative)

Kurz: 0.81 (strong)

Signal:(57.111) Same movement expected

Metacrine, Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Metacrine, Inc. Korrelation - Währung/Rohstoff

-0.39
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.17
( neutral )

-0.21
( neutral )

0.48
( neutral )

Metacrine, Inc. Finanzdaten

Annual	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.40

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.40

FY	2020
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.436

FY	2019
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Metacrine, Inc. Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.580 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Metacrine, Inc. Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.580	2023-06-21
Last Dividend	$0.580	2023-06-21
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.580	--
Avg. Dividend % Per Year	43.27%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$1.160 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.580	129.80%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.766	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.835	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	13.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	9.85	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.177	-1.500	7.06	-10.00	[0 - 0.6]
interestCoverageTTM	-50.81	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.120	2.00	-0.373	-0.747	[0 - 30]
freeCashFlowPerShareTTM	-1.120	2.00	-0.560	-1.120	[0 - 20]
debtEquityRatioTTM	0.246	-1.500	9.01	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-3.34	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.578

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.400	1.000	-0.141	0	[1 - 100]
returnOnEquityTTM	-0.835	2.50	-6.68	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.120	2.00	-0.373	-1.120	[0 - 30]
dividendYielPercentageTTM	99.76	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.120	2.00	-0.373	-0.747	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-0.413

Metacrine, Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.